Nuvectis Pharma is a pre-revenue, clinical-stage biotech pursuing precision oncology and complement-mediated disease therapies through a capital-efficient virtual model. Its investment value is concentrated in four clinical assets: NXP100, NXP200, NXP900, and NXP800. The June 2026 Haisco licensing deal materially upgraded the pipeline by adding late-stage complement and BRAF programs with meaningful clinical validation. NXP100’s once-daily oral profile and superior PNH data versus Soliris, plus NXP200’s paradox-breaker BRAF mechanism, create substantial upside, but execution, financing, dilution, and regulatory risks remain central.

Nuvectis Pharma, Inc. (NVCT) Investment Analysis

1. Executive Summary:

Nuvectis Pharma, Inc. (NASDAQ: NVCT) is a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of innovative, rationally designed precision medicines for serious oncology indications and complement-mediated inflammatory diseases.[1, 2, 3] Operating with a capital-efficient, virtual business model, the company identifies and in-licenses high-potential therapeutics from prestigious academic institutions and global pharmaceutical groups.[4, 5] Nuvectis subsequently leads clinical and manufacturing development to advance these candidates toward regulatory approvals in major global markets.[4, 5]

As a clinical-stage entity, Nuvectis does not currently generate product revenues, reporting a net loss of $6.05 million for the first quarter of 2026.[6, 7] Consequently, its business model does not yet feature conventional customer-driven revenue streams, commercial geographies, or transactions.[4, 6] Instead, its economic value resides entirely within its pipeline of four primary clinical assets:

• NXP100 (formerly HSK39297): A once-daily, orally administered Complement Factor B inhibitor (CFBi) in late-stage development for Paroxysmal Nocturnal Hemoglobinuria (PNH), Immunoglobulin A Nephropathy (IgAN), and Lupus Nephritis.[2, 8, 9]
• NXP200 (formerly HSK42360): A brain-penetrant, oral "paradox-breaker" BRAF inhibitor in Phase 1b development for primary brain tumors and advanced solid tumors harboring BRAF Class I (V600) and Class II/III mutations.[9, 10, 11]
• NXP900: A selective, oral, first-in-class SRC/YES1 kinase inhibitor currently undergoing Phase 1b monotherapy and combination trials for advanced solid tumors.[12, 13]
• NXP800: An oral GCN2 kinase activator in Phase 1b development, being evaluated for endometrial and prostate cancers, as well as an investigator-sponsored trial in cholangiocarcinoma.[12, 14]

The company's primary target segments consist of patients suffering from rare, chronic alternative complement pathway disorders and specific molecularly driven solid tumors.[4, 12, 15] Once commercialized, the primary customers will be specialty pharmacies, hospital groups, and clinics.[15] Under the ex-China licensing agreement executed with Haisco Pharmaceutical Group on June 22, 2026, Nuvectis holds exclusive rights to commercialize NXP100 and NXP200 in all worldwide territories outside of Greater China (NXP100 also excludes India and select Southeast Asian countries).[5, 10]

Physicians and patients choose Nuvectis's clinical candidates over standard-of-care alternatives due to three primary competitive differentiators: enhanced dosing convenience, superior efficacy demonstrated in head-to-head trials, and a unique mechanism of action that overcomes established drug-resistance pathways.[16, 17] For example, NXP100 offers a once-daily oral profile that challenges the twice-daily oral dosing of Novartis's Fabhalta and eliminates the need for bi-weekly intravenous infusions of AstraZeneca’s C5 blockbusters Soliris and Ultomiris.[11, 17, 18] Similarly, NXP200 suppresses mutated BRAF signaling without triggering the "paradoxical activation" seen in older BRAF inhibitors, eliminating the necessity of toxic combination regimens with MEK inhibitors.[9, 19]

---

2. Business Drivers & Strategic Overview:

In-Depth Pipeline Analysis and Clinical Efficacy

Nuvectis's strategic value and revenue-generating potential are driven by its newly expanded clinical pipeline, which underwent a major transformation on June 22, 2026, through an ex-China in-licensing agreement with Haisco Pharmaceutical Group for NXP100 and NXP200.[5, 16]

NXP100 (HSK39297) - Late-Stage Oral Complement Factor B Inhibitor

NXP100 targets the alternative pathway of the complement immune system by selectively inhibiting Factor B.[5] It is designed as an optimized chemical analog of Novartis's approved twice-daily oral CFBi Fabhalta (iptacopan).[9, 17] Chemical modifications were introduced to improve the pharmacokinetic properties, enabling a once-daily dosing regimen while maintaining safety and clinical potency.[17]

In China, Haisco has already submitted two Marketing Authorization Applications (MAAs) to the National Medical Products Administration (NMPA) for PNH, with approvals expected in late 2026 or early 2027.[2, 17] The applications are supported by robust Phase 3 data:

Phase 3 Study / Cohort	Patient Population	Dosing Regimen	Primary Endpoint (Hb $\ge$ 12 g/dL without transfusion)	Comparative/P-Value
NCT06799546 (Active Comparator) [2]	73 adult treatment-naïve Chinese PNH patients [2]	NXP100 once daily vs. Soliris (eculizumab) IV [2, 11]	NXP100: 59.5% (95% CI: 43.2, 75.7) Soliris: 8.3% (95% CI: 2.8, 19.4) [2]	Superiority met; $p < 0.001$ [2]
NCT07052838 (Single-Arm) [2]	36 adult Chinese PNH patients with C5 failure [2]	NXP100 once daily [2, 11]	NXP100: 52.8% (95% CI: 35.5, 69.6) [2]	Met primary efficacy definition [2]

Beyond PNH, NXP100 completed a randomized, double-blind, placebo-controlled Chinese Phase 2 trial in IgA Nephropathy ($N=45$).[20] Results showed a rapid, clinically meaningful reduction in proteinuria (measured by 24h-UPCR) that widened over time: a 33% reduction at Week 4, 45.3% at Week 12 (primary endpoint), and 57.7% at Week 24 compared to placebo.[20] NXP100 also demonstrated excellent estimated Glomerular Filtration Rate (eGFR) preservation, indicating disease-modifying potential comparable to leading injectable BAFF/APRIL inhibitors under development.[17, 20] Nuvectis is preparing Investigational New Drug (IND) submissions in the United States to initiate global clinical trials outside China.[17]

NXP200 (HSK42360) - Oral Paradox-Breaker BRAF Inhibitor

NXP200 is a brain-penetrant oral small molecule designed to inhibit mutated BRAF class 1 (V600) and class 2 (non-V600/fusions) alterations.[9, 21] First-generation BRAF inhibitors (such as dabrafenib and encorafenib) suffer from a structural liability: they trigger "paradoxical activation" of the MAPK pathway in cells with wild-type BRAF or RAS mutations.[9, 19] This drives tumor resistance, rapid disease recurrence, and secondary skin cancers, forcing clinicians to co-administer MEK inhibitors.[19, 22]

As a paradox-breaker, NXP200 prevents the RAF dimerization that underlies paradoxical activation, enabling its use as a highly selective monotherapy.[19, 23] In an ongoing Chinese Phase 1b clinical trial, a second-generation salt formulation has shown improved pharmacokinetics and exposure over the previous free-base version.[9] Early clinical data presented at the 2026 AACR conference demonstrated single-agent efficacy:

Indication / Study	Patient Baseline	Efficacy Highlights	Clinical Timeline & Milestones
Recurrent Glioma (Adult) [9, 24]	Heavily pretreated, including prior progression on BRAF/MEK combinations [9, 24]	ORR: >40% single-agent response rate, including one complete response.[9, 24]	Ongoing Chinese Phase 1b expansion; Nuvectis preparing U.S. IND filings.[9, 17]
Durable Solid Tumor Responses [9, 24]	Advanced NSCLC, Colorectal, Papillary Thyroid cancer [9, 24]	Durable, multi-month objective responses observed.[24, 25]	Ongoing Phase 1b monitoring; expansion into targeted non-CNS cohorts.[8, 17]

NXP900 - Selective SRC/YES1 Family Kinase Inhibitor

NXP900 represents Nuvectis’s incumbent precision oncology asset, discovered at the University of Edinburgh and in-licensed in 2021.[26, 27] While older multi-kinase inhibitors (such as dasatinib, bosutinib, and saracatinib) only achieve partial SRC pathway shutdown, NXP900 utilizes a Type 1.5 selective conformation that blocks both the catalytic and scaffolding functions of SRC, yielding a complete shut down of the pathway.[12, 28, 29]

NXP900 completed a Phase 1a trial in patients with advanced solid tumors and a drug-drug interaction (DDI) study in healthy volunteers.[12] The DDI study confirmed NXP900 is a weak inhibitor of CYP3A and CYP2B6, raising the concentrations of co-administered midazolam and bupropion by less than 2-fold.[29] This profile enables combinations with other therapies without altering their metabolism.[13] Currently, NXP900 is undergoing US-based Phase 1b monotherapy studies in patients harboring Hippo pathway alterations (FAT1-4 mutations, YAP1/TAZ amplifications) or YES1 amplifications, and a combination trial with osimertinib (Tagrisso) in EGFR-mutant NSCLC to disrupt SRC-mediated bypass resistance.[13, 30, 31] Maasachussetts General Hospital's Dr. Zofia Piotrowska is leading the study.[16, 31] Preliminary Phase 1b clinical data is expected in the summer of 2026.[1]

NXP800 - GCN2 Kinase Activator

Initially developed for ARID1a-mutated ovarian cancer, Grade 4 thrombocytopenia observed during clinical trials led management to stop ovarian development and re-evaluate NXP800 in endometrial and prostate cancers.[12, 14] The asset is also being evaluated in an investigator-sponsored trial for cholangiocarcinoma at the Mayo Clinic.[12]

Economic and Patent-Backed Competitive Moat

Nuvectis is constructing a defensible competitive moat protected by three primary barriers:

1. Robust Composition-of-Matter IP: The company’s pipeline is heavily protected by issued composition-of-matter patents that prevent competitors from introducing generic alternatives.[17] NXP100’s patent protection extends to the year 2043 [17], NXP200's to 2042 [17], and NXP900's to April 2036, with opportunities for patent term extensions in key territories.[4]
2. High Clinical Switching Costs: PNH, IgA Nephropathy, and advanced cancers are severe, life-threatening conditions requiring chronic, lifelong therapeutic management.[2, 15, 16] Once a patient is clinically stabilized on a highly convenient, once-daily oral drug like NXP100, the switching costs of transitioning back to bi-weekly intravenous infusions of Soliris or twice-daily oral Fabhalta are clinically and operationally restrictive.[9, 16]
3. Dosing and Efficacy Barriers: Capturing market share from existing oral competitors (like Fabhalta) will be driven by NXP100's once-daily oral profile, which cuts the patient pill burden in half.[9, 11] In oncology, NXP200's ability to operate as a single-agent monotherapy without requiring MEK combinations limits toxic side effects like rash and fever, creating a significant safety moat over early-generation competitors.[22]

Total Addressable Market (TAM) Opportunity

The commercial potential of Nuvectis’s newly structured pipeline spans several multi-billion-dollar indications:

• PNH and IgA Nephropathy alternative pathway markets: The global PNH market is expected to surpass $5.0 billion in 2026, with AstraZeneca’s injectable C5 inhibitors (Soliris and Ultomiris) capturing $4.5 billion of that total.[18] The market is expected to double to over $10.0 billion within 8 years.[18] Coupled with IgA Nephropathy (IgAN)—a rapidly growing segment where Novartis’s Fabhalta has projected peak sales of $5.0 to $10.0 billion—the combined TAM for oral CFB inhibitors is estimated to exceed $20.0 billion over the next decade.[18]
• BRAF Class 1 and 2 Oncology Market: The current first-generation BRAF/MEK combination market is valued at approximately $4.0 billion annually.[5, 8] Because NXP200 targets both class 1 (V600) and class 2 (fusions/non-V600) mutations, its addressable market is significantly larger than early-generation inhibitors, which are structurally limited to class 1 mutations.[16]
• EGFR-Mutant Non-Small Cell Lung Cancer: Tagrisso represents a multi-billion-dollar franchise; NXP900's positioning as a combination therapy to overcome acquired resistance targets the largest addressable market within mutant NSCLC.[13, 24]

Competitive Landscape

Nuvectis's positioning against key industry competitors indicates a transition from an early-stage biotech to a late-stage developer [9, 16]:

• Versus AstraZeneca (Soliris/Ultomiris): In head-to-head randomized Phase 3 trials in Chinese PNH patients, NXP100 demonstrated superiority on all key endpoints.[2, 8] Its 59.5% transfusion-free hemoglobin normalization rate far outperformed Soliris's 8.3% ($p<0.001$).[2] NXP100's oral route of administration provides a massive convenience barrier to AstraZeneca's high-priced intravenous injections ($6,523 per vial in the U.S.).[15, 18]
• Versus Novartis (Fabhalta): Novartis's Fabhalta, launched in 2024, is the only FDA-approved CFB inhibitor.[11, 18] While Fabhalta requires twice-daily dosing, NXP100's chemically optimized PK profile allows for once-daily dosing, offering a significant compliance advantage in lifelong indications.[2, 11, 17]
• Versus Fore Biotherapeutics (Plixorafenib): In the paradox-breaker BRAF space, Fore Biotherapeutics' plixorafenib (FORE8394) received FDA Breakthrough Therapy Designation in April 2026 for adult BRAF V600E high-grade glioma based on an ongoing Phase 2 study demonstrating a 67% ORR in MAPK inhibitor-naïve patients.[21, 32] While Fore leads in regulatory timing, NXP200’s clinical data indicates broader single-agent activity outside the central nervous system (CNS), including durable responses in colorectal and thyroid cancers.[17]
• Versus Early-Generation Multi-Kinase Inhibitors: NXP900 holds a clear selectivity advantage over older multi-kinase inhibitors like dasatinib, achieving complete pathway shutdown with minimal off-target toxicities.[12, 28, 29]

Nuvectis is gaining market ground by leveraging Haisco's late-stage, clinically validated assets to minimize early-stage clinical trial risks.[8]

---

3. Financial Performance & Valuation:

Q1 2026 Financial Results and Revenue Breakdown

Nuvectis announced its Q1 2026 financial results on May 5, 2026, for the quarterly period ended March 31, 2026.[6] The company generated $0 in product revenue, which met analyst expectations, as all pipeline candidates remain in clinical stages.[4, 6, 33]

• Operating Deficits: Nuvectis reported an operating loss of $6.26 million, compared to $5.57 million in Q1 2025.[1] The widened deficit was primarily driven by clinical, manufacturing, and public company expenses.[1, 7]
• Net Income/Loss: Net loss widened to $6.05 million ($0.26 loss per common share outstanding), compared to a net loss of $5.33 million ($0.27 loss per common share outstanding) in Q1 2025.[1, 7] The EPS loss of $(0.26) met Wall Street consensus expectations.[34]
• R&D Expenses: Research and development expenses were $4.11 million, compared to $3.68 million in Q1 2025.[1] This $0.43 million increase was primarily driven by a $0.4 million increase in clinical manufacturing and a $0.2 million increase in clinical trial expenses, partially offset by a $0.5 million reduction in licensing fees.[1]
• G&A Expenses: General and administrative expenses rose to $2.15 million from $1.89 million in Q1 2025, driven by professional and consulting services related to public company expenses.[1]
• Balance Sheet and Cash Runway: Cash and cash equivalents totaled $25.13 million as of March 31, 2026, down from $31.63 million as of December 31, 2025.[1] Total assets were $25.40 million.[1] Total liabilities (all current) were $11.18 million, down from $13.30 million, consisting of $4.70 million in accounts payable and $6.45 million in employee benefits.[1, 6] The accumulated deficit reached $105.74 million.[1, 6] Prior to the Haisco deal, management stated that existing cash was sufficient to fund operations for at least 12 months, with runway extending into the second half of 2027.[6, 16, 35]

The following table summarizes the company's financial results:

Financial Metric (USD in thousands, except per share)	Q1 2026 (Ended Mar 31, 2026)	Q1 2025 (Ended Mar 31, 2025)	YOY Change (%)	FY 2025 (Ended Dec 31, 2025)
Product Revenue [4, 33]	$0	$0	—	$0
R&D Expenses [1]	$4,106	$3,680	+11.6%	$18,153
G&A Expenses [1]	$2,154	$1,888	+14.1%	$9,421
Operating Loss [1]	$(6,260)	$(5,568)	+12.4%	$(27,574)
Finance Income [1]	$210	$236	-11.0%	$1,132
Net Loss [1]	$(6,050)	$(5,332)	+13.5%	$(26,442)
Basic & Diluted EPS [1, 7]	$(0.26)	$(0.27)	+3.7%	$(1.32)
Cash and Cash Equivalents [1]	$25,130	$30,000	-16.2%	$31,634
Accumulated Deficit [1, 6]	$(105,737)	$(78,577)	+34.6%	$(99,687)

Guidance Changes and Management Commentary

As a pre-revenue clinical biotech, Nuvectis does not issue quarterly financial or revenue guidance.[4, 6] However, during the Q1 earnings call, CEO Ron Bentsur highlighted the progress of NXP900's Phase 1b clinical program [1]:

"2026 is off to a good start for Nuvectis as we advance the NXP900 Phase 1b clinical program which continues to enroll patients at top sites in the US in both the monotherapy and combination arms of the program." [1]

Mr. Bentsur also confirmed clinical timelines, stating that the company expects a preliminary data readout from the NXP900 Phase 1b study in the summer of 2026.[1]

Share Price and Valuation Impact of Clinical Events

The Q1 2026 earnings release on May 5, 2026, triggered a positive market reaction.[36] NVCT shares gained 9.22% on the publishing day on very high volume (3.6x relative daily volume), adding approximately $23 million to the company's valuation and lifting its market cap to $269.21 million at that time.[36]

This move was followed by a massive technical and valuation repricing yesterday on June 22, 2026, upon the announcement of the Haisco licensing agreement.[5, 37] Shares surged 19.61% in a single day to close at $16.53.[37] Today, June 23, 2026, the stock trades at $17.44 on the Cboe BZX exchange.[38]

Following the Haisco announcement, analyst Joseph Pantginis of H.C. Wainwright maintained his Buy rating on Nuvectis and raised his 12-month price target from $13.00 to $39.00.[37] The revised price target is based on an updated clinical net present value (rNPV) model that integrates the newly acquired ex-China rights to NXP100 and NXP200 [37]:

• NXP100 (PNH): Modeled with a 55% probability of success (PoS) based on positive Chinese pivotal Phase 3 data and filed MAAs.[37]
• NXP100 (IgAN): Modeled with a 40% PoS based on positive Phase 2 data and the ongoing Chinese Phase 3 trial.[37, 39]
• NXP200 (Glioma): Modeled with a conservative 15% PoS based on Phase 1b data showing a >40% response rate.[9, 37]
• NXP900: Maintained at a 25% PoS reflecting its current Phase 1b stage of clinical development.[7, 37]

Wall Street consensus is bullish, with a median price target of $26.00, ranging from a low of $17.00 to a high of $39.00.[40]

Core Financial Valuation Drivers

Because Nuvectis is pre-revenue, traditional valuation multiples like Price-to-Earnings ($P/E$) or Price-to-Sales ($P/S$) are not meaningful metrics.[38, 41] The stock trades at a premium Price-to-Book ($P/B$) ratio of 19.98 to 30.83, reflecting the market value of its proprietary intellectual property relative to its thin balance sheet equity.[38]

To connect valuation to the business model, investors must focus on the following drivers:

1. Haisco Transaction Financing Requirements: The Haisco licensing agreement requires up to $40 million in upfront and near-term payments, and $1.42 billion in milestone payments.[5, 9] However, the agreement is subject to explicit financing conditions that Nuvectis must meet to ensure it has sufficient capital.[5] If it fails to secure this funding, the agreement could collapse.[5]
2. ATM and Dilution Strategy: To satisfy these financing conditions, Nuvectis will utilize its active $150.0 million Form S-3 shelf registration and remaining $60.0 million at-the-market (ATM) equity program.[6, 36] This will cause dilution to existing shareholders, expanding the share count from 26.5 million to an estimated 40.0–45.0 million over the next five years.[6, 42]
3. Revenue Trajectory post-2028: Financial projections assume $0 in product revenue through 2027.[33] If NXP100 obtains FDA approval, initial commercial sales are expected to launch by late 2028, with consensus estimating $30.0 million in revenue by December 31, 2028, and a rapid, high-margin sales ramp post-2029.[33]

---

4. Risk Assessment & Macroeconomic Considerations:

Nuvectis operates in a high-risk, high-reward biopharmaceutical sector.[4, 43] A detailed risk assessment is outlined below, categorized by urgency and impact on the investment thesis:

Company-Specific Execution and Pipeline Risks

• Haisco Financing Failure (High Urgency): The ex-China rights to NXP100 and NXP200 are contingent on Nuvectis meeting specific financing conditions.[5] If the company fails to raise the required capital under favorable terms to fund the $40 million in upfront and near-term payments, Haisco may terminate the licensing agreement.[5, 9]
• Ex-China Clinical Replication Failure: While NXP100 demonstrated an impressive 59.5% response rate in Chinese PNH patients, there is no guarantee that global Phase 3 trials in Western populations will replicate these results.[2, 8] Differences in patient demographics or trial protocols could negatively affect efficacy or safety outcomes.
• Heavy Dilution Pressure: Satisfying licensing commitments and funding global trials will require extensive capital.[4, 5] Aggressive utilization of the $150.0 million S-3 shelf and $60.0 million ATM program will significantly dilute current shareholders.[6, 36]

Competitive, Demand, and Industry Structure Risks

• Intense Market Competition: Nuvectis competes directly with pharmaceutical giant Novartis, whose twice-daily oral CFB inhibitor Fabhalta is already approved and seeing strong market adoption.[11, 17] AstraZeneca’s C5 blockbusters (Soliris/Ultomiris) also command a deep clinical and distribution network.[17, 18] In the paradox-breaker oncology space, Fore Biotherapeutics' plixorafenib is further along in development, having secured FDA Breakthrough Therapy Designation in April 2026.[32]
• Orphan Market Constraints: PNH is a rare, niche disease with a limited patient population.[4, 15] If alternative treatments saturate the market, NXP100's peak sales potential could be constrained.
• Outsourced Operational Dependency: As a virtual company with only 12 employees, Nuvectis relies entirely on third-party Contract Research Organizations (CROs) for clinical trials and Contract Manufacturing Organizations (CMOs) for drug production.[4, 40] Any manufacturing delay or compliance failure by these third parties could derail clinical timelines.[4]

Regulatory, Legal, and Macroeconomic Risks

• US and Global Regulatory Obstacles: Nuvectis must secure IND clearances from the US FDA and other international regulators to begin ex-China trials.[4, 17] Any safety signal or clinical hold could delay development timelines by 12–18 months.[4]
• Interest Rate and Capital Market Sensitivities: Small-cap biotech companies are highly sensitive to macroeconomic conditions and interest rate environments.[4, 43] Sustained high-interest rates depress early-stage valuations and raise the cost of equity financing, making capital preservation critical.[4]

Strategic Risk Differentiation

• What Could Go Wrong (Near-Term Hurdles): The company could fail to satisfy the Haisco transaction financing conditions [5]; NXP900 Phase 1b trials could show poor efficacy or excessive toxicity [1, 4]; or the FDA could delay IND clearance for NXP100, halting the planned global trial expansion.[4, 17]
• Early Warning Signs (Diagnostic Indicators): Slow patient recruitment for the NXP900/osimertinib combination trial [16, 31]; a delay in NXP900's preliminary Phase 1b data readout, originally scheduled for Summer 2026 [1]; or heavy, distressed use of the ATM program at declining share prices.[6, 7]
• What Would Most Damage the Long-Term Thesis (Fundamental Failures): A clinical failure of NXP100 in global Phase 3 trials, or a failure to replicate the 59.5% transfusion-free hemoglobin normalization rate, would eliminate Nuvectis's primary valuation driver and destroy the core investment thesis.[2, 37]

---

5. 5-Year Scenario Analysis:

The following five-year model projects the valuation and total return trajectories for Nuvectis from its current trading price of $17.44 USD.[38]

High Case (20% Probability)

The High Case assumes outstanding clinical and regulatory execution across all pipelines. NXP100 satisfies its financing conditions [5], obtains FDA/EMA approvals for PNH and IgA Nephropathy by 2030, and captures a 3% share ($600 million) of the ex-China complement market.[18] NXP200 secures breakthrough approvals in glioma, capturing $150 million of the BRAF oncology market.[8, 16] Total Year 5 revenue reaches $750 million. The company's virtual business model yields a 30% net margin, resulting in $225 million in net income. Dilution is managed, with outstanding shares increasing to 45.0 million to fund global clinical programs, resulting in an EPS of $5.00 USD. Applying a 30x P/E multiple (commensurate with high-growth, commercial biotechs) yields an implied share price of $150.00 USD.

• Total 5-Year Return: 760.1%
• Annualized Return: 53.8%

Base Case (60% Probability)

The Base Case assumes NXP100 achieves FDA approval in PNH and IgAN, launching commercially by 2029–2030, while NXP900 advances to Phase 3. NXP100 captures a conservative 1.5% combined market share, generating $300 million in ex-China revenue.[18] Net margins of 25% yield a net income of $75 million. Share dilution is managed, with outstanding shares increasing to 40.0 million to satisfy licensing commitments, resulting in an EPS of $1.88 USD. Applying a conservative 25x P/E multiple yields an implied share price of $47.00 USD.

• Total 5-Year Return: 169.5%
• Annualized Return: 21.9%

Low Case (20% Probability)

The Low Case assumes clinical failure. NXP100 global trials fail to replicate Chinese Phase 3 results, or safety issues emerge, and NXP900 development is halted.[4, 37] Nuvectis fails to satisfy the Haisco transaction financing conditions, terminating the ex-China rights.[5] The company is forced to restructure or operate as a highly distressed micro-cap, relying on aggressive dilutive raises to survive. Year 5 revenue is $0, net income is negative, and outstanding shares balloon to 50.0 million. The equity trades at a distressed liquidation value of $1.50 USD per share.

• Total 5-Year Return: -91.4%
• Annualized Return: -38.6%

Probability-Weighted Target Share Price

The probability-weighted target share price over five years is calculated as:

$Weighted\ Target\ Price = (150.00 \times 0.20) + (47.00 \times 0.60) + (1.50 \times 0.20) = 30.00 + 28.20 + 0.30 = \$58.50\ USD$

The following table summarizes the five-year scenario trajectory:

Scenario	Year 5 Revenue (USD)	Margin / Earnings Assumption	Valuation Multiple Assumption	Current Share Price (USD)	Implied Future Share Price (USD)	5-Year Total Return	Annualized Return	Subjective Probability
High Case	$750M [18]	30% Net Margin / $5.00 EPS	30x P/E Multiple	$17.44 [38]	$150.00	760.1%	53.8%	20%
Base Case	$300M [18]	25% Net Margin / $1.88 EPS	25x P/E Multiple	$17.44 [38]	$47.00	169.5%	21.9%	60%
Low Case	$0 [4]	Distressed / Negative EPS	Distressed Asset	$17.44 [38]	$1.50	-91.4%	-38.6%	20%
Weighted	$330M	Blended EPS	rNPV Blended	$17.44	$58.50	235.4%	27.4%	100%

ASYMMETRIC UPSIDE OPPORTUNITY

---

6. Qualitative Scorecard:

To evaluate the non-financial, structural, and operational durability of Nuvectis, the company has been scored on a scale of 1–10 across ten distinct categories:

Management Alignment: 9/10

The co-founding management team possesses high operational and equity alignment.[44, 45] Chairman and CEO Ron Bentsur owns 13.9% of outstanding common shares, valued at approximately $50.8 million.[45, 46] Over the past 12 months, insiders have completed four distinct open-market purchases totaling $1.44 million, with zero insider sales.[47, 48] Compensation is heavily geared toward performance-based milestones.[49, 50]

Revenue Quality: 2/10

Because Nuvectis is in the clinical-development phase, current revenue quality is poor.[4, 6] Trailing product revenues are $0.[4, 41] Future revenue quality, however, is expected to be high, consisting of highly recurring, price-inelastic, orphan-drug commercial sales or high-margin licensing royalties.[5, 15]

Market Position: 7/10

NXP100 occupies a competitive position due to its once-daily oral dosing profile, which challenges Novartis's twice-daily oral Fabhalta and AstraZeneca's injectables.[9, 11] While Nuvectis is a smaller player, the superior Phase 3 Hb data vs Soliris positions it to capture market share over time.[2, 18]

Growth Outlook: 9/10

The expansion of the pipeline via the June 2026 Haisco deal transforms the company's growth trajectory.[5, 37] Nuvectis has transitioned from an early-stage oncology player into a late-stage complement and precision-medicine developer targeting markets valued at over $24 billion combined.[5, 8, 18]

Financial Health: 4/10

Nuvectis maintains a clean balance sheet with $0 in long-term debt.[42] However, its cash position of $25.13 million as of March 31, 2026, is insufficient to cover the upfront payments ($20–$40 million) and clinical development costs of the newly licensed Haisco assets.[1, 5] Significant, dilutive equity financings will be required to fund operations.[1, 4]

Business Viability: 6/10

The underlying science of NXP100, NXP200, and NXP900 is validated, and their clinical profiles are strong.[2, 16, 51] However, the business model remains vulnerable to clinical-trial outcomes and regulatory hurdles.[4]

Capital Allocation: 7/10

Management has demonstrated high capital efficiency, successfully in-licensing late-stage, derisked assets via back-end-loaded structures ($1.42 billion in milestones concentrated in successful commercial scenarios) rather than overpaying upfront.[5] However, managing the milestone burden will test allocation skills.[5]

Analyst Sentiment: 10/10

Wall Street sentiment is bullish.[40] Analysts unanimously hold Buy ratings, with a high price target of $39.00 USD from H.C. Wainwright.[37, 40]

Profitability: 1/10

The company is unprofitable, recording a net loss of $26.4 million in fiscal year 2025 and $6.05 million in Q1 2026, with an accumulated deficit of $105.7 million.[6, 35] Profitability is not expected until at least 2029–2030.[33]

Track Record: 7/10

The management team has a strong track record.[29, 44] CEO Ron Bentsur previously led Keryx Biopharmaceuticals and UroGen Pharma, successfully guiding multiple precision assets through FDA approvals, clinical validation, and commercial launch.[44]

Overall Blended Score: 6.2/10

The qualitative scorecard highlights a transformative pipeline expansion that holds high clinical potential but remains constrained by near-term funding hurdles.[4, 5, 8]

TRANSFORMATIVE LATENT VALUE

---

7. Conclusion & Investment Thesis:

The strategic in-licensing of NXP100 and NXP200 from Haisco Pharmaceutical Group has altered the investment thesis for Nuvectis Pharma.[5, 37] By securing ex-China rights to two clinical-stage assets with high clinical validation, Nuvectis has evolved from a speculative, early-stage oncology player into a diversified, late-stage biopharmaceutical company.[9, 16]

The investment thesis rests on key upcoming catalysts:

1. NXP900 Clinical Progress: Preliminary Phase 1b data readouts are expected in Summer 2026, which will validate its role as a monotherapy or combination agent with osimertinib.[1, 16]
2. Closing and Financing of the Haisco Transaction: Satisfying the financing conditions to finalize the license agreement will transition the portfolio to a late-stage platform.[5]
3. U.S. and Ex-China Regulatory Milestones: Preparing and filing IND submissions for NXP100 and NXP200 will allow the company to initiate global trials.[17]
4. China Approvals: Chinese regulatory approvals for NXP100 in PNH are anticipated in late 2026 and early 2027.[17]

While clinical trial risks, commercial competition from Novartis, and imminent equity dilution via its $150 million shelf registration remain real [6, 11, 37], the risk-reward profile appears asymmetric.[37] The underlying Phase 3 PNH data and once-daily dosing convenience provide NXP100 with a strong competitive foundation to address a $20 billion market.[2, 18]

ASYMMETRIC GROWTH PLATFORM

---

8. Technical Analysis, Price Action & Short-Term Outlook:

NVCT shares are in a powerful technical uptrend, closing recently at $16.53 USD and trading near $17.44 USD.[37, 38] The stock is trading significantly above its 200-day simple moving average of $10.79 USD and its exponential moving average of $10.74 USD, indicating strong long-term bullish momentum.[52] Daily technical indicators show a Strong Buy signal, with the MACD at 1.06 [52] and the 14-day RSI at 84.39.[52] Although the RSI indicates overbought conditions in the short term, the powerful momentum driven by the Haisco transaction suggests further consolidation near these highs rather than a sharp retreat.[52, 53]

STRONG BULLISH MOMENTUM

---

1. Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights, https://www.biospace.com/press-releases/nuvectis-pharma-inc-reports-first-quarter-2026-financial-results-and-business-highlights
2. Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds - BioSpace, https://www.biospace.com/press-releases/nuvectis-announces-strategic-portfolio-expansion-via-license-agreement-for-ex-china-rights-with-haisco-pharmaceutical-group-for-two-potentially-best-in-class-clinical-stage-compounds
3. Nuvectis Pharma Raises $15 Million and In-Licenses Exclusive Worldwide Rights to Novel Selective HSF1 Pathway Inhibitor from the CRT Pioneer Fund - BioSpace, https://www.biospace.com/nuvectis-pharma-raises-15-million-and-in-licenses-exclusive-worldwide-rights-to-novel-selective-hsf1-pathway-inhibitor-from-the-crt-pioneer-fund
4. Nuvectis Pharma, Inc. SEC 10-K Report - TradingView, https://www.tradingview.com/news/tradingview:c57b33c176c5b:0-nuvectis-pharma-inc-sec-10-k-report/
5. Nuvectis (NASDAQ: NVCT) inks Haisco deal for NXP100 and BRAF drug NXP200, https://www.stocktitan.net/sec-filings/NVCT/8-k-nuvectis-pharma-inc-reports-material-event-fc0f5682139c.html
6. Nuvectis Pharma (NASDAQ: NVCT) posts $6.1M Q1 loss with $25.1M cash - Stock Titan, https://www.stocktitan.net/sec-filings/NVCT/10-q-nuvectis-pharma-inc-quarterly-earnings-report-2b1d0ee2e5ef.html
7. Nuvectis Pharma, Inc. Q1 2026: Net loss $(6.05M), EPS $(0.26) — 10-Q Summary, https://www.tradingview.com/news/tradingview:b3560ec0cae06:0-nuvectis-pharma-inc-q1-2026-net-loss-6-05m-eps-0-26-10-q-summary/
8. Nuvectis Expands Pipeline with Ex-China Rights to Best-in-Class Complement Factor B and Paradox-Breaker BRAF Inhibitors in $10B+ Markets 126 - Minichart, https://www.minichart.com.sg/2026/06/23/nuvectis-expands-pipeline-with-ex-china-rights-to-best-in-class-complement-factor-b-and-paradox-breaker-braf-inhibitors-in-10b-markets-126/
9. Nuvectis Acquires Haisco Assets in $1.46B Deal - AllSci, https://allsci.com/news/licensing-deals/nuvectis-licenses-haiscos-late-stage-factor-b-inhibitor-and-braf-program-in-usd-1-4b-deal/
10. Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications - PR Newswire, https://www.prnewswire.com/news-releases/haisco-enters-into-exclusive-license-agreement-with-nuvectis-for-two-drug-candidates-in-oncology-and-complement-indications-302807803.html
11. Nuvectis, Haisco ink up to $1.4B deal for two late-stage programs - BioSpace, https://www.biospace.com/deals/nuvectis-haisco-ink-up-to-1-4b-deal-for-two-late-stage-programs
12. Nuvectis | Innovative precision medicine for the treatment of complement-related conditions and oncology, https://nuvectis.com/
13. Investor Event to discuss the NXP900 Phase 1b program in advanced solid tumor including the combination with Osimertinib in NSCLC - Nuvectis Pharma, Inc., https://nuvectis.com/wp-content/uploads/NXP900-Phase-1b-KOL-Event-December-2nd-2025-3.pdf
14. Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study - BioSpace, https://www.biospace.com/press-releases/nuvectis-pharma-provides-final-clinical-data-update-from-the-nxp800-phase-1b-study-in-ovarian-cancer-and-reports-completion-of-the-nxp900-phase-1a-dose-escalation-study
15. Global Soliris Market Size, Share and Analysis, 2026-2033, https://www.coherentmarketinsights.com/industry-reports/global-soliris-market
16. Nuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar Markets - WebDisclosure, https://www.webdisclosure.com/press-release/nuvectis-lands-major-haisco-deal-for-two-potentially-best-in-class-compounds-in-multi-billion-dollar-markets-NwtIx64UaTj
17. Nuvectis Pharma, Inc. (NVCT) Discusses Strategic In-Licensing Deal and Expansion Into Complement-Mediated Diseases and Oncology Prepared Remarks Transcript | Seeking Alpha, https://seekingalpha.com/article/4916710-nuvectis-pharma-inc-nvct-discusses-strategic-in-licensing-deal-and-expansion-into-complement
18. Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds | Markets Insider, https://markets.businessinsider.com/news/stocks/nuvectis-announces-strategic-portfolio-expansion-via-license-agreement-for-ex-china-rights-with-haisco-pharmaceutical-group-for-two-potentially-best-in-class-clinical-stage-compounds-1036264810
19. Fore Bio's plixorafenib receives FDA Breakthrough Therapy status for BRAF-mutated glioma, https://allsci.com/news/fore-bios-plixorafenib-receives-fda-breakthrough-therapy-status-for-braf-mutated-glioma/
20. Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds - GlobeNewswire, https://www.globenewswire.com/news-release/2026/06/22/3315199/0/en/nuvectis-announces-strategic-portfolio-expansion-via-license-agreement-for-ex-china-rights-with-haisco-pharmaceutical-group-for-two-potentially-best-in-class-clinical-stage-compoun.html
21. FDA Grants Breakthrough Therapy Designation to Plixorafenib for BRAF V600E Glioma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways, https://www.targetedonc.com/view/fda-grants-breakthrough-therapy-designation-to-plixorafenib-for-braf-v600e-glioma
22. FORE Biotherapeutics Announces Positive Outcome From a Planned Interim Efficacy Analysis for the FORTE Basket Study Evaluating Plixorafenib as a Monotherapy for Recurrent or Progressive BRAF V600 Primary CNS Tumors, https://fore.bio/fore-biotherapeutics-announces-positive-outcome-from-a-planned-interim-efficacy-analysis-for-the-forte-basket-study-evaluating-plixorafenib-as-a-monotherapy-for-recurrent-or-progressive-braf-v600-prim/
23. Abstract CT273: FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers - AACR Journals, https://aacrjournals.org/cancerres/article/86/8_Supplement/CT273/783331/Abstract-CT273-FORTE-A-phase-2-master-protocol
24. Nuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar Markets - FinanceWire - Financial Press Release Distribution, Finance PR, https://financewire.com/2026/06/22/nuvectis-lands-major-haisco-deal-for-two-potentially-best-in-class-compounds-in-multi-billion-dollar-markets/
25. SEC Filings - Nuvectis, https://nuvectis.com/sec-filings
26. NXP-900 - Drug Targets, Indications, Patents - Patsnap Synapse, https://synapse.patsnap.com/drug/6e6c0e590702451fa5a53743781bb9ab
27. Life-saving cancer drug takes next step in clinical development, https://institute-genetics-cancer.ed.ac.uk/life-saving-cancer-drug-takes-next-step-in-clinical-development
28. Nuvectis Pharma, Inc., https://nuvectis.com/wp-content/uploads/NVCT-Corporate-Presentation_January-2025.pdf
29. Nuvectis Pharma, Inc., https://nuvectis.com/wp-content/uploads/December-2025_NVCT-Corporate-Presentation2.pdf
30. September-2025_NVCT-Corporate-Presentation.pdf - Nuvectis Pharma, Inc., https://nuvectis.com/wp-content/uploads/September-2025_NVCT-Corporate-Presentation.pdf
31. NCT07315113 | Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer | ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT07315113
32. FORE Biotherapeutics Receives Breakthrough Therapy Designation for Plixorafenib, https://fore.bio/fore-biotherapeutics-receives-breakthrough-therapy-designation-for-plixorafenib/
33. NVCT / Nuvectis Pharma, Inc. - Forecast, Price Target, Estimates, Predictions - Fintel, https://fintel.io/sfo/us/nvct
34. Nuvectis Pharma: NVCT Stock Price Quote & News | Robinhood, https://robinhood.com/us/en/stocks/NVCT/
35. Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights - SEC.gov, https://www.sec.gov/Archives/edgar/data/1875558/000110465926013049/tm265090d1_ex99-1.htm
36. Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights, https://www.stocktitan.net/news/NVCT/nuvectis-pharma-inc-reports-first-quarter-2026-financial-results-and-104wz195tpv1.html
37. H.C. Wainwright raises Nuvectis Pharma price target to $39 on pipeline expansion By Investing.com, https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-nuvectis-pharma-price-target-to-39-on-pipeline-expansion-93CH-4755289
38. NVCT Stock Price Quote - Nuvectis Pharma Inc - Morningstar, https://www.morningstar.com/stocks/xnas/nvct/quote
39. Nuvectis Pharma Expands Pipeline with Exclusive Ex-China Rights to Haisco's NXP100 and NXP200 Clinical-Stage Candidates | Quiver Quantitative, https://www.quiverquant.com/news/Nuvectis+Pharma+Expands+Pipeline+with+Exclusive+Ex-China+Rights+to+Haisco%E2%80%99s+NXP100+and+NXP200+Clinical-Stage+Candidates
40. Nuvectis Pharma Inc (NVCT) Stock Price & News - Google Finance, https://www.google.com/finance/beta/quote/NVCT:NASDAQ
41. NVCT Stock Forecast 2026 - Nuvectis Price Targets & Predictions - Ticker Nerd, https://tickernerd.com/stock/nvct-forecast/
42. Companies Like Nuvectis Pharma (NASDAQ:NVCT) Are In A Position To Invest In Growth, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nvct/nuvectis-pharma/news/companies-like-nuvectis-pharma-nasdaqnvct-are-in-a-position
43. Nuvectis Pharma Inc. (NVCT) Surges 5.2% – Key Levels to Watch - Gap and Reverse, https://www.antiquemotorcycle.org/news/blink/Nuvectis-Pharma-Inc-NVCT-Surges-52-Key-Levels-to-Watch-28-12299
44. About - Nuvectis Pharma, Inc., https://nuvectis.com/about-us/
45. Nuvectis Pharma, Inc. Insider Trading & Ownership Structure - Simply Wall St, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nvct/nuvectis-pharma/ownership
46. Nuvectis Pharma, Inc. (NVCT) Leadership & Management Team Analysis - Simply Wall St, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nvct/nuvectis-pharma/management
47. Nuvectis Pharma (NVCT) Insider Trading Activity 2026 - MarketBeat, https://www.marketbeat.com/stocks/NASDAQ/NVCT/insider-trades/
48. Nuvectis Pharma (NVCT) Expands Portfolio with Strategic License Agreement - GuruFocus, https://www.gurufocus.com/news/8924989/nuvectis-pharma-nvct-expands-portfolio-with-strategic-license-agreement
49. NVE Corporation (NVEC) outlines CEO handoff, board expansion and 2026 say-on-pay vote, https://www.stocktitan.net/sec-filings/NVEC/def-14a-nve-corp-new-definitive-proxy-statement-8638458b5c30.html
50. NUVECTIS PHARMA INC Executive Salaries & Other Compensation, https://www.salary.com/research/executive-compensation/nuvectis-pharma-inc-executive-salary
51. Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial, https://www.globenewswire.com/news-release/2026/05/05/3287554/0/en/nuvectis-pharma-inc-reports-first-quarter-2026-financial-results-and-business-highlights.html
52. NVCT Technical Analysis, RSI and Moving Averages - Investing.com, https://www.investing.com/equities/nuvectis-pharma-technical
53. Nuvectis licenses two clinical-stage drugs from Haisco - Investing.com, https://www.investing.com/news/company-news/nuvectis-licenses-two-clinicalstage-drugs-from-haisco-93CH-4752357